Here are the main hurdles for Novo Nordisk
The Danish diabetes giant has presented the weakest sales growth in ten years. The main culprit is a decline in sales in North America.
by Viktor Brandt Kærgaard
Novo Nordisk has performed a negative adjustment of its expectations for 2014 following a modest sales growth of just 7% in Q1. The sales growth is the weakest in ten years and the reason for the disappointing result is to be found overseas, where the company’s diabetes business grew by just 1% in the quarter.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
